140 related articles for article (PubMed ID: 27615359)
1. Papillary Thyroid Carcinoma: A Malignant Tumor with Increased Antioxidant Defense Capacity.
Rovcanin BR; Gopcevic KR; Kekic DLj; Zivaljevic VR; Diklic ADj; Paunovic IR
Tohoku J Exp Med; 2016 Oct; 240(2):101-11. PubMed ID: 27615359
[TBL] [Abstract][Full Text] [Related]
2. Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma.
Tabur S; Korkmaz H; Özkaya M; Elboğa U; Tarakçıoglu M; Aksoy N; Akarsu E
Tumour Biol; 2015 Sep; 36(10):7549-56. PubMed ID: 25916207
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinoma.
Tabur S; Aksoy ŞN; Korkmaz H; Ozkaya M; Aksoy N; Akarsu E
Tumour Biol; 2015 Apr; 36(4):2667-74. PubMed ID: 25434875
[TBL] [Abstract][Full Text] [Related]
4. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
5. [Expression and significance of serum E-cadherin in patients with papillary thyroid carcinoma].
Sun L; Wang DM; Zhang WJ; Zhang J; Wu JF
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 31(2):123-126. PubMed ID: 29871201
[No Abstract] [Full Text] [Related]
6. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Ziros PG; Manolakou SD; Habeos IG; Lilis I; Chartoumpekis DV; Koika V; Soares P; Kyriazopoulou VE; Scopa CD; Papachristou DJ; Sykiotis GP
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1422-7. PubMed ID: 23766517
[TBL] [Abstract][Full Text] [Related]
7. Total oxidant/antioxidant status in sera of patients with thyroid cancers.
Wang D; Feng JF; Zeng P; Yang YH; Luo J; Yang YW
Endocr Relat Cancer; 2011 Dec; 18(6):773-82. PubMed ID: 22002574
[TBL] [Abstract][Full Text] [Related]
8. Different Expression of Erythrocyte Sedimentation Rate and C-reactive Protein in Papillary Thyroid Carcinoma and Nodular Goiter.
Hou X; Jiang L; Chen C; Zhu X; Ge M
Clin Lab; 2015; 61(7):793-9. PubMed ID: 26299079
[TBL] [Abstract][Full Text] [Related]
9. Redox Status and Antioxidative Cofactor Metals Influence Clinical and Pathological Characteristics of Papillary Thyroid Carcinoma and Colloid Goiter.
Rovcanin B; Stojsavljevic A; Kekic D; Gopcevic K; Manojlovic D; Jovanovic M; Knezevic S; Zivaljevic V; Diklic A; Paunovic I
Biol Trace Elem Res; 2020 Oct; 197(2):349-359. PubMed ID: 31811573
[TBL] [Abstract][Full Text] [Related]
10. The correlation of the total antioxidant status (TAS), total oxidant status (TOS) and paraoxonase activity (PON1) with smoking.
Aslan R; Kutlu R; Civi S; Tasyurek E
Clin Biochem; 2014 Apr; 47(6):393-7. PubMed ID: 24440837
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Meng XY; Zhang Q; Li Q; Lin S; Li J
J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
[TBL] [Abstract][Full Text] [Related]
12. RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.
Su X; He C; Ma J; Tang T; Zhang X; Ye Z; Long Y; Shao Q; Shao J; Yang A
PLoS One; 2016; 11(11):e0165596. PubMed ID: 27802347
[TBL] [Abstract][Full Text] [Related]
13. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC.
Hu J; Li C; Liu C; Zhao S; Wang Y; Fu Z
Cancer Biomark; 2017; 18(1):87-94. PubMed ID: 28085013
[TBL] [Abstract][Full Text] [Related]
14. Lipid peroxidation and antioxidants status in human malignant and non-malignant thyroid tumours.
Stanley JA; Neelamohan R; Suthagar E; Vengatesh G; Jayakumar J; Chandrasekaran M; Banu SK; Aruldhas MM
Hum Exp Toxicol; 2016 Jun; 35(6):585-97. PubMed ID: 26270564
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304
[TBL] [Abstract][Full Text] [Related]
16. [The expression and significance of trefoil factor 3 and SDF-1/CXCR4 biological axis in papillary thyroid carcinoma].
Xue G; Huang J; Zhang H; Zhang W; Wu J; Shang X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jan; 28(2):108-12. PubMed ID: 24738314
[TBL] [Abstract][Full Text] [Related]
17. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
18. Thyroglobulin antibody levels do not predict disease status in papillary thyroid cancer.
Smooke-Praw S; Ro K; Levin O; Ituarte PH; Harari A; Yeh MW
Clin Endocrinol (Oxf); 2014 Aug; 81(2):271-5. PubMed ID: 24494778
[TBL] [Abstract][Full Text] [Related]
19. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
